VRTX analyst estimates

Vertex (VRTX) analyst ratings, the average price target and its range, and every firm's latest call.

VRTX analyst ratings and price targets

DateFirmCallTarget
Nov 3, 2026TD CowenVertex (VRTX) PT Raised to $575 at TD Cowen$575.00
Nov 3, 2026Wells FargoVertex (VRTX) PT Raised to $650 at Wells Fargo$650.00
Nov 3, 2026J.P. MorganVertex (VRTX) PT Raised to $570 at JPMorgan$570.00
Nov 3, 2026Cantor FitzgeraldVertex (VRTX) PT Raised to $619 at Cantor Fitzgerald$619.00
Oct 8, 2026RBC CapitalVertex Pharmaceuticals price target raised to $576 from $570 at RBC Capital$576.00
Sep 28, 2026UBSVertex Pharmaceuticals price target raised to $615 from $585 at UBS$615.00
Sep 23, 2026JefferiesVertex (VRTX) PT Raised to $640 at Jefferies$640.00
Sep 22, 2026H.C. WainwrightH.C. Wainwright Reiterates Buy Rating on Vertex (VRTX)$641.00
Sep 1, 2026Goldman SachsVertex Pharmaceuticals added to US Conviction List at Goldman Sachs$653.00
Sep 1, 2026Morgan StanleyVertex Pharmaceuticals resumed with an Overweight at Morgan Stanley$665.00
Aug 11, 2026BernsteinBernstein SocGen Reiterates Outperform Rating on Vertex (VRTX)$608.00
Aug 10, 2026Wolfe ResearchVertex (VRTX) PT Raised to $562 at Wolfe Research$562.00
Aug 5, 2026BarclaysVertex Pharmaceuticals price target raised to $617 from $615 at Barclays$617.00
Aug 5, 2026Truist FinancialVertex Pharmaceuticals price target raised to $565 from $560 at Truist$565.00
Aug 4, 2026Cantor FitzgeraldVertex Pharmaceuticals price target raised to $595 from $590 at Cantor Fitzgerald$595.00